1. Home
  2. GH vs ST Comparison

GH vs ST Comparison

Compare GH & ST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GH
  • ST
  • Stock Information
  • Founded
  • GH 2011
  • ST 1916
  • Country
  • GH United States
  • ST United States
  • Employees
  • GH N/A
  • ST N/A
  • Industry
  • GH Medical Specialities
  • ST Industrial Machinery/Components
  • Sector
  • GH Health Care
  • ST Industrials
  • Exchange
  • GH Nasdaq
  • ST Nasdaq
  • Market Cap
  • GH 6.1B
  • ST 4.4B
  • IPO Year
  • GH 2018
  • ST 2010
  • Fundamental
  • Price
  • GH $40.64
  • ST $26.44
  • Analyst Decision
  • GH Strong Buy
  • ST Buy
  • Analyst Count
  • GH 20
  • ST 13
  • Target Price
  • GH $48.40
  • ST $39.08
  • AVG Volume (30 Days)
  • GH 2.6M
  • ST 2.0M
  • Earning Date
  • GH 05-08-2025
  • ST 04-28-2025
  • Dividend Yield
  • GH N/A
  • ST 1.81%
  • EPS Growth
  • GH N/A
  • ST N/A
  • EPS
  • GH N/A
  • ST 0.85
  • Revenue
  • GH $739,016,000.00
  • ST $3,932,764,000.00
  • Revenue This Year
  • GH $19.11
  • ST N/A
  • Revenue Next Year
  • GH $21.44
  • ST $4.71
  • P/E Ratio
  • GH N/A
  • ST $31.26
  • Revenue Growth
  • GH 31.04
  • ST N/A
  • 52 Week Low
  • GH $15.81
  • ST $24.91
  • 52 Week High
  • GH $50.89
  • ST $43.14
  • Technical
  • Relative Strength Index (RSI)
  • GH 46.62
  • ST 39.12
  • Support Level
  • GH $34.88
  • ST $26.01
  • Resistance Level
  • GH $45.00
  • ST $29.25
  • Average True Range (ATR)
  • GH 3.11
  • ST 1.05
  • MACD
  • GH -0.28
  • ST -0.21
  • Stochastic Oscillator
  • GH 51.89
  • ST 10.97

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About ST Sensata Technologies Holding plc

Sensata Technologies is a global supplier of sensors for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.

Share on Social Networks: